Nine Pharma Companies Ink Deals to Lower Drug Prices

Here’s a‍ breakdown of the key information from‍ the provided‍ text regarding Trump’s drug pricing ‍deals:

Core of the Deals:

* ⁢⁤ Price Reductions: ⁤Nine major pharmaceutical companies have agreed to lower drug prices for⁢ Americans.
* “Most⁤ Favored Nation” Pricing: They will sell existing drugs to Medicaid patients at the lowest ⁤prices offered in other countries (“most favored nation” prices) and guarantee similar pricing for new medicines.
* TrumpRx Website: The companies will list popular drugs on Trump’s upcoming direct-to-consumer website, TrumpRx, launching in january.
* ⁢ U.S. Manufacturing investment: The deals are linked to companies investing further in U.S. manufacturing,possibly shielding them from Trump’s planned pharmaceutical tariffs.

Specific Company Pledges (Examples):

* Bristol Myers Squibb: Will offer its blockbuster blood thinner, Eliquis, for‍ free to Medicaid patients.
* Gilead: Will offer ⁣its hepatitis C treatment, Epclusa, at a discounted price through a new program.
* Sanofi: Will ‍offer discounts of nearly 70% on certain medicines⁣ through TrumpRx ⁣and other platforms.
*⁤ ‍ Merck: Will offer three diabetes ‍medications ⁣(Januvia, Janumet, Janumet XR) at a roughly 70% discount to cash-paying patients, and extend⁤ this‍ to a potential new cholesterol pill if approved.

Companies Not ‍Yet⁤ Onboard (as of the article):

* Johnson & Johnson (expected⁢ to join soon)
* AbbVie
* Regeneron

Trump’s Claims:

* He calls this “the⁤ greatest victory for patient affordability in the history of American health care.”
* He states⁣ 14 out of 17 major pharmaceutical companies⁤ have agreed to lower prices.

Uncertainties:

* ⁤ ⁤ The ⁣full terms of the deals haven’t been released, so the breadth of ⁣their impact is unclear.

the article highlights Trump’s “most favored nation” policy, which aims to end what ⁣he calls “global freeloading” by increasing drug prices outside the U.S.⁤ and lowering them within the ⁣country.